THE ONE Forum
The ONE Forum 2020
Thanks to attendees’ outstanding participation and engagement, The ONE Forum 2020 was a resounding success. Continue your journey of learning and innovation by viewing the following on-demand sessions at your convenience.
Sessions available on-demand
If you registered for The ONE Forum 2020, you can access all of the on-demand sessions by logging into the conference platform with the same login you used to access the conference. Access The ONE Forum 2020 platform.
If you were unable to register for the event, access the on-demand sessions below that are available for further education:
Fresh or Frozen: The Impact of Cryopreservation on Transplant Outcomes
This session presents the results of several recently completed CIBMTR studies evaluating the impact of graft cryopreservation on outcomes in allogeneic hematopoietic cell transplantation.
Search Strategy Advice: Identifying Optimal Sources Using Transplant Outcomes Data
This session describes how transplant centers can use Search Strategy Advice, a service offered by NMDP/Be The Match, to aid in optimizing donor and cord blood unit source selection through the use of transplant outcomes data. The matching guidelines are also reviewed through case studies.
What’s in Your Wallet? - Exploring Graft Sources
This session provides a comprehensive overview of key graft sources available for patients in a transplant center’s portfolio of treatment options. Experts in the BMT community provide insights on graft source selection by piecing together patient profiles, disease stages, clinical experience and evidence to deliver successful outcomes for patients.
Advancements in the Field of Cord Blood - Beyond the Innovation Lab
This session showcases developments in the field of cord blood between Sept. 2019 and Sept. 2020. Topics include operational achievements, cord blood community advancements, data trends, and special project updates.
Impact of New Cell and Gene Therapies on Utilization of BMT and HSCT
In this session, a panel of industry and clinical experts explore how growth in novel cell and gene therapy approvals could impact the future use of BMT and HSCT.